-
公开(公告)号：US12110337B2
公开(公告)日：2024-10-08
申请号：US17045143
申请日：2019-04-03
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Li-Sheng Lu , Mark J. Selby , Alan J. Korman , Shrikant Deshpande , Mohan Srinivasan , Jun Zhang , Haichun Huang , Guodong Chen , Richard Y. Huang , Ekaterina Deyanova
IPC: C07K16/28 , A61K39/395 , A61P35/00 , A61K39/00
CPC classification number: C07K16/2878 , A61K39/39541 , A61P35/00 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/74 , C07K2317/75 , C07K2317/92
Abstract: This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.
-
公开(公告)号：US11981734B2
公开(公告)日：2024-05-14
申请号：US17668807
申请日：2022-02-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
IPC: C07K16/28 , A61K39/395 , A61K47/68 , A61P35/00 , C07K1/22 , C12N5/071 , C12N15/85 , C12P21/00 , G01N33/68 , A61K39/00
CPC classification number: C07K16/2803 , A61K39/3955 , A61K47/6849 , A61P35/00 , C07K1/22 , C12N5/0682 , C12N15/85 , C12P21/005 , G01N33/68 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N2510/02 , C12N2800/107
Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
公开(公告)号：US11591392B2
公开(公告)日：2023-02-28
申请号：US16697653
申请日：2019-11-27
Applicant: Bristol-Myers Squibb Company
Inventor： Xiao Min Schebye , Mark J. Selby , Michelle Minhua Han , Christine Bee , Andy X. Deng , Anan Chuntharapai , Brigitte Devaux , Huiming Li , Paul O. Sheppard , Alan J. Korman , Daniel F. Ardourel , Ekaterina Deyanova , Richard Huang , Guodong Chen , Michelle Kuhne , Hong-An Truong
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
-
4.发明授权公开(公告)号：US11084881B2
公开(公告)日：2021-08-10
申请号：US16578987
申请日：2019-09-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Changyu Wang , Nils Lonberg , Alan J. Korman , Mark J. Selby , Mohan Srinivasan , Karla Henning , Michelle Minhua Han , Guodong Chen , Richard Huang , Indrani Chakraborty , Haichun Huang , Susan Wong , Huiming Li
IPC: C12N15/13 , C07K16/28 , A61K39/395 , G01N33/68 , G01N33/574 , A61K39/00 , A61K47/68
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US10556948B2
公开(公告)日：2020-02-11
申请号：US15364612
申请日：2016-11-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Mohan Srinivasan , Shrikant Deshpande , Qihong Zhao , Huadong Sun , Ginger Rakestraw , Guodong Chen , Richard Y. Huang , Steven Sheriff , Cristian Rodriguez , John P. Throup , Rose A. Dibella
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
-
Patent Agency Ranking
公开(公告)号：US10533052B2
公开(公告)日：2020-01-14
申请号：US16017489
申请日：2018-06-25
Applicant: Bristol-Myers Squibb Company
Inventor： Xiao Min Schebye , Mark J. Selby , Michelle Minhua Han , Christine Bee , Andy X. Deng , Anan Chuntharapai , Brigitte Devaux , Huiming Li , Paul O. Sheppard , Alan J. Korman , Daniel F. Ardourel , Ekaterina Deyanova , Richard Huang , Guodong Chen , Michelle Kuhne , Hong-An Truong
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
-
7.发明授权公开(公告)号：US10465010B2
公开(公告)日：2019-11-05
申请号：US15646558
申请日：2017-07-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Changyu Wang , Nils Lonberg , Alan J. Korman , Mark J. Selby , Mohan Srinivasan , Karla Henning , Michelle Minhua Han , Guodong Chen , Richard Huang , Indrani Chakraborty , Haichun Huang , Susan Wong , Huiming Li
IPC: C07K16/00 , C07H21/00 , C07K16/28 , A61K39/395 , G01N33/68 , G01N33/574 , A61K39/00 , A61K47/68
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US10358490B2
公开(公告)日：2019-07-23
申请号：US15694374
申请日：2017-09-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Brenda L. Stevens , Alison Witte , Mark W. Rixon , Josephine M. Cardarelli , Thomas D. Kempe , Scott R. Presnell , Mohan Srinivasan , Susan C. Wong , Guodong Chen , Hui Wei , Stanley R. Krystek , Lumelle A. Schneeweis , Paul O. Sheppard , Indrani Chakraborty
IPC: A61K39/395 , C07K16/24 , C07K16/46 , A61K39/00
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
-
公开(公告)号：US10100129B2
公开(公告)日：2018-10-16
申请号：US15520638
申请日：2015-11-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria Jure-Kunkel , Guodong Chen , John S. Sack , Richard Y. Huang , Martin J. Corbett , Joseph E. Myers, Jr. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: A61K39/00 , C07K16/40 , C07K16/28 , A61K47/68 , C07K16/30 , A61K39/395 , A61K45/06 , G01N33/574
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.
-
公开(公告)号：US20160145350A1
公开(公告)日：2016-05-26
申请号：US14994828
申请日：2016-01-13
Applicant: Bristol-Myers Squibb Company
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Huang , Martin J. Corbett , Joseph E. Myers, JR. , Liang Schweizer , Sandra V. Hatcher
IPC: C07K16/40 , G01N33/573 , A61K39/395 , A61K47/48 , C07K16/30 , A61K45/06
CPC classification number: C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3061 , C07K16/3069 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/72 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , G01N33/573 , G01N2333/916
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
Abstract translation: 本发明提供分离的单克隆抗体，特别是人抗体，其以高亲和力结合人类分化簇73（CD73），并且抑制CD73的活性，并任选介导抗体依赖性CD73内化。 还提供了编码本发明抗体的核酸分子，表达载体，宿主细胞和用于表达本发明的抗体的方法。 还提供了免疫偶联物，双特异性分子和包含本发明抗体的药物组合物。 本发明还提供了使用本发明的抗体抑制表达CD73的肿瘤细胞生长的方法，包括治疗各种癌症的方法。
-
-
-
-
-
-
-
-
-
Search Results
58
records
(took 0.059 seconds)
